Calcium-mediated zoledronate loading onto carbon nanohorns

Authors:
Publisher website
Google Scholar
Abstract
Previously, we showed that the anti-osteoclast effect of zoledronate (ZOL), a type of bisphosphonate, is enhanced when it is used as a nanocomposite comprising ZOL, an “oxidized single-walled carbon nanohorn (OxCNH) with a spherical shape” and calcium phosphate (CaP). This nanocomposite, termed OxCNH-CaP-ZOL, is a potential therapeutic agent for patients with bone fragility associated with metastatic bone cancer. Because OxCNH-CaP-ZOL contains by-products that comprise CaP–ZOL nanocomposites, the aim of this study was to prepare more sophisticated nanocomposites lacking such by-products; it was achieved by reducing the availability of calcium and phosphate ions during the preparation process. In this new nanocomposite, ZOL loading onto OxCNH was mediated by Ca, and therefore it is referred to as OxCNH-Ca-ZOL. Because the amount of ZOL in OxCNH-Ca-ZOL was about half that in OxCNH-CaP-ZOL and murine macrophages (RAW264.7 cells) took up less OxCNH-Ca-ZOL than OxCNH-CaP-ZOL, the amount of ZOL inside RAW264.7 cells exposed to OxCNH-Ca-ZOL was less than that inside cells exposed to OxCNH-CaP-ZOL. Despite this drawback, OxCNH-Ca-ZOL had suppressive effects similar to OxCNH-CaP-ZOL on the viability of RAW264.7 cells. The reason for these phenomena is not clear; however, it could be due to the differences in the ZOL release rate between OxCNH-Ca-ZOL and OxCNH-CaP-ZOL. In addition, receptor activator of nuclear factor kappa-B ligand (RANKL)-induced differentiation of RAW264.7 cells into osteoclasts was suppressed by co-administration of RANKL with OxCNH-Ca-ZOL as effectively as with OxCNH-CaP-ZOL, and indeed, their effects were greater than those of free ZOL.
Funding Information
  • Japan Society for the Promotion of Science (JP17H01584, JP20K21914, JP22H00582, JP23K17870)

This publication has 20 references indexed in Scilit: